Home \| Site Map \| \| Powered by WhyPark.com
	GENERICSMD.COM - Avodart, Dutasteride, Dutas 0,5mg, Veltride, hair loss, Intas, Dr. Reddy's

GENERICSMD.COM - Avodart, Dutasteride, Dutas 0,5mg, Veltride, hair loss, Intas, Dr. Reddy's

Good Neighbor Pharmacy to Enter NASCAR with Diversified Racing Solutions
Good Neighbor Pharmacy (GNP) is teaming with Diversified Racing Solutions (DRS) to compete initially in NASCAR's Busch Series with a goal of reaching the Sprint Cup Series in 2010. The five year agreement calls for GNP to lend its community pharmacy brand as the DRS flagship sponsor; the venture will be primarily funded by associate sponsor relationships. GNP will also fund country-wide community outreach activities that compliment the racing schedule. Driver and car manufacturer will be announced shortly.

Group Health Cooperative Implements Zynchros.com to Increase Pharmacy Data Consolidation and Collaboration: Zynchros Technology Streamlines Proces
In a measure to increase efficiency and enhance internal processes, Group Health Cooperative has implemented Zynchros.com, the leading, on-demand formulary management technology, for their commercial and Medicare Part D lines of business.

Rimonabant Health Web Site Launches New Forum
A new forum on the Rimonabant Health web site allows consumers to interact and discuss their experiences with the Rimonabant series of drugs.

The Best Deal: The Lipitor and Atkins Diet Combination
One of the modern miracles in medicine is the development of the statin variety of drugs. Lipitor is the brand name for atorvastatin calcium, which is one of these statin varieties of drugs. Lipitor is one of the more heavily prescribed brands of cholesterol lowering medications today. It is, therefore, not surprising that the combination of Lipitor and the Atkins diet is being considered by many dieticians. For the vast majority of patients on these kinds of medicines, high counts of the unwanted type of cholesterol are a thing of the past. This is important for those who find that their cholesterol numbers increase when they are on the Atkins diet.

iLinc Web Conferencing Software Helps Creighton University's Doctor of Pharmacy Program Graduate More Students: Better Enabled Distance Learning
When Creighton University launched the nation's first Web-based entry-level doctor of pharmacy program in 2001 it didn't have the powerful Web collaboration tools it needed to satisfy the distance-learning students' needs. A Jesuit university located in Omaha, Neb., the school's Web conferencing technology allowed for some basic features, but offered very little interactivity beyond the basics. Worse, the technology only supported one session at a time, which clearly wouldn't satisfy the broad learning and collaboration requirements of the program.

Paxil Resource Web Site Launched by Williams Kherkher
Williams Kherkher launch a Paxil Resource web site in response to the prescription drug, paxil.

Cialis: For successful sexual intercourse
Think about your 20 years back stage, if you are celebrating your 60th birthday, then certainly you would have felt that you don?t have the sex power same as you have now. You want to give a tremendous sexual encounter to your female friend at that moment but you can not, because of erectile dysfunction problem.

Rimonabant Acomplia a Diet Pill
Acomplia (Rimonabant) is is an oral prescription medication to treat obesity. It woks on the principle of blocking the CB-1 receptors situated in the Endo-cannabinoid system. Consumption of Acomplia primarily blocks the functioning of these receptors, resulting in a decrease of your normal appetite. A reduced appetite means that you would eat less, and in turn loose weight.

"Patient Safety and Peak Performance Through Pharmacy Training" From Baxa Corporation Focuses On Pharmaceutical Compounding Safety Concerns
"Patient Safety and Peak Performance Through Pharmacy Training" from Baxa Corporation is now posted on PublicRelationsNewsroom.com for media and professional access. The article discusses the history of sterile compounding in pharmacy practice, current state, and the need for a purpose-built facility that provides practical, hands-on training in pharmacy preparation and regulatory compliance in order to achieve the level of patient safety and performance excellence required in today's pharmacy environments.

Viagra OCT Just in Time for Valentines Day
For the first time ever, the anti-impotence drug Viagra will be sold over-the-counter in the UK. A UK pharmacy called Boots Manchester will launch sales of over-the-counter Viagra starting this Wednesday, (Valentines Day).

Propecia
One a day will keep the depression away.To many men (and women) today, the bathroom mirror is the mortal enemy.

Canada Pharmacy Now Offers Contact Lenses
Canada Pharmacy is now offering a variety of contact lens options at www.canadapharmacy.com.

Pharmacy Jobs: Northern Nevada Medical Center
The whole world is facing a severe and problematic shortage of qualified laboratory and medical personnel. Third world countries are suffering because their doctors and medical staff are immigrating to meet excess demand for high-paid medical positions in Europe.

What Is Sildenafil Citrate? It Is Viagra!
Viagra has become a success in the entire world since 1996, year in which it makes it appearance. The company that patented Viagra was Pfizer. Since that time, men have been very happy with this product that definitely has improved their sexual life.

Focus Express Mail Pharmacy Discounts Prescription Co-pays by 20 Percent to Diabetes and Chronic Illness Sufferers
Focus Express Mail Pharmacy, a national internet-based mail-order pharmacy, offers reduced co-payments for people with diabetes and other chronic illnesses, and provides a 20% reduction in co-pays to its insurance qualified customers.

History of Acomplia during 2007

History is a strange beast. You can only see it when you turn and look back. The closer it is to you, the less easy it is to see. The difficulty with writing about acomplia is that you must always start somewhere. Wherever you pick in time, the real question is how far back to look. What have we taken for granted? What gaps have we left? So in this article, we catch up with the past. Just to make sure that we have everyone on the same virtual page.

Acomplia (generic name rimonabant) has been an authorised medication in the EU since June 2006 for use in adult patients where the BMI exceeds 30 or the BMI exceeds 27 with associated risk factors such as diabetes. In all cases, it can only be prescribed in conjunction with a hypocaloric diet and physical exercise.

2007 was quite a good year. In March, the French government announced that acomplia was the first selective cannabinoid-1 receptor antagonist to be reimbursable by Social Security. Patients with prescriptions are entitled to recover 35% of the cost. The fact that no other medication has been approved for the subsidised treatment of obesity, gives acomplia a big market advantage in France.

In April, the Swiss government followed suit, placing acomplia on the mandatory reimbursement list both for the treatment of patients with type 2 diabetes with a BMI of 28 or more, and for the treatment of any patient with a BMI greater than 35.

But acceptance was not limited to Europe. April also saw an announcement from the Brazilian government that acomplia can be marketed to patients with a BMI over 30 or greater than 27 where there are risk factors present.

In July, the European Medicines Agency (EMEA) modified its blanket approval for acomplia. It formally accepted evidence that there may be psychiatric side effects and so issued a directive that acomplia should not be prescribed to patients who have been diagnosed with major depression or who are already receiving antidepressants. In one sense, there was nothing new about this because the risk was identified when approval was first given in June 2006. But the EMEAs Committee for Medicinal Products for Human Use (CHMP) changed the level of warning.

The CHMP holds a general brief for monitoring the safety of medicines licensed for use in the EU. In June, it therefore requested Sanofi-Aventis, the French manufacturer, to submit all the available data it had in its possession on these side effects. In July, it concluded that the benefits of using acomplia continued to outweigh the possible disadvantages except in the cases where a patient was more seriously depressed. Thus, the warning now directs doctors either not to prescribe acomplia where a patient has been diagnosed as severely depressed, or to discontinue the use of acomplia if a patient subsequently becomes depressed. By publicising its findings, the CHMP was also taking steps to alert patients and their carers of the potential risk of using acomplia in relation to depression.

In November, the European Commission accepted EMEAs positive impression of acomplia, reacting favourably to the results of the SERENADE study (Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients), in which newly diagnosed type 2 diabetic patients showed significantly improved glycemic control and a reduction in cardio-metabolic risk factors.

It is important to recognise that SERENADE is part of a more extensive Phase IIIb clinical trial program being carried out round the world. At present, there are more than 25,000 participants in eight further studies to study the effect of acomplia in the treatment of type 2 diabetes. These results are expected during the next two years.

John Scott wrote this article to help you find out more about losing weight. Visit http://www.newageweightloss.com/blog/history-of-acomplia-during-2007.html today for more information.